期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

用基因芯片技术测定健康人群P4502C9基因多态性 被引量：10

Determination of the P450 2C9 genetic polymorphisms in healthy volunteers utilizing oligonucleotide microarray
下载PDF
导出
摘要 目的探讨基因芯片技术在P4502C9基因分型中应用的可行性,研究中国人群P4502C9基因多态性。方法用基因芯片技术测定169例中国健康志愿者P4502C9基因分型,并用直接测序法对结果进行验证。结果169例中国健康志愿者中,共发现9名P4502C91/3基因型,P4502C93/3基因型1名,无P4502C92,P4502C94和P4502C95变异。结论基因芯片法适用于中国健康人群P4502C9基因分型研究,健康人群P4502C93等位基因频率为0.03。 Objective To study the P450 2C9 genetic polymorphisms in Chinese healthy volunteers using oligonucleotide microarray. Methods P450 2C9 genotype was determined by oligonucleotide microarray. Part of the genotyping results was confirmed by direct sequencing. Results Nine heterozygous alleles of P450 2C9*1/*3 and 1 homozygous mutant alleles were found in 169 subjects. No mutant alleles of P450 2C9*2, P450 2C9*4 and P450 2C9*5 were detected. Conclusion Oligonucleotide microarray was reliable for determination of P450 2C9 genetic polymorphisms. The P450 2C9*3 allele frequency was 0.03 in Chinese.
作者 陈騉 王睿 文思远 李健 王升启
机构地区 中国海洋大学海洋药物与食品研究所 解放军总医院临床药理室 军事医学科学院放射医学研究所
出处 《中国临床药理学杂志》 CAS CSCD 北大核心 2005年第3期176-179,共4页 The Chinese Journal of Clinical Pharmacology
基金 国家863计划资助项目(2002AA2Z341L)
关键词 P450 2C9 基因多态性 基因芯片 P450 2C9 genetic polymorphisms oligonucleotide microarray
分类号 R319 [医药卫生—基础医学] R977.15 [医药卫生—药品]
  • 相关文献

参考文献2

二级参考文献22

  • 1Lin Cai~1 Shun-Zhang Yu~2 Zuo-Feng Zhang~3 1 Department of Epidemiology,Fujian Medical University,Fuzhou 350004,Fujian Province,China2 Department of Epidemiology,Shanghai Medical University,Shanghai 200032,China3 Department of Epidemiology,UCLA School of Public Health,Los Angeles California,USA.Cytochrome P450 2E1 genetic polymorphism and gastric cancer in Changle,Fujian Province[J].World Journal of Gastroenterology,2001,7(6):792-795. 被引量：25
  • 2[1]Lee S, Kim JM, Chung CS, Cho K J, Kim JH. Polymorphism in CYP2C9 as a non-critical factor of warfarin dosage adjustment in Korean patients[J]. Arch Pharm Res, 2003; 26 (11): 967 -72
  • 3[2]eSchwarz UI. Clinical relevance of genetic polymorphisrms in the human CYP2C9 gene[J]. Eur J Clin Invest, 2003;33(2) :23 -30
  • 4[3]Bozina N, Granic P, Lalic Z, Tramisak I, Lovric M, Stavljenic RA. Genetic polymorphisms of cytochromes P450: CYP2C9,CYP2C19, and CYP2D6 in Croatian population[J]. Croat Med J, 2003;44(4) :425 - 8
  • 5[4]Yang JQ, Morin S, Verstuyft C, Fan LA, Zhang Y, Xu CD, et al. Frequency of cytochrome P450 2C9 allelic variants in the Chinese and French populations[J]. Fundam Clih Pharmacol,2003; 17(3) :373 - 6
  • 6[5]Takahashi H, WilkinsonGR, Caraco Y, Muszkat M, Kim RB,Kashima T, et al. Population diffcrenees in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients [J]. Clin Pharmacol Ther, 2003; 73 (3): 253 - 63
  • 7[6]Xie HG, Prasad HC, Kim RB, and Stein CM. CYP2C9 allelic variants: ethnic distribution and functional significance[J]. Adv Drug Deliv Rev, 2002;54(10): 1257 - 70
  • 8[7]Inoue K, Yamazaki H, Imiya K, Akasaka S, Guengerich FP,Shimada T. Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4'-hydroxylation activities in livers of Japanese and Caucasian Populations[J]. Pharmacogenetics, 1997 ;7(2): 103 - 113
  • 9[8]Kidd RS, Straughn AB, Meyer MC, Blaisdell J, Goldstein JA,Dalton JT. Pharmacokinetics of chlorpheniramine, phenytoin,glipizide and in an individual homozygous for the CYP2C9 * 3allele[J]. Pharmacogenetics, 1999: 9(1): 71 - 80
  • 10[9]Van der Weide J, Steijns LS, van Weelden MJ, de Haan K.The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement [J]. Pharmacogenetics, 2001; 11(4) :287 - 91

共引文献23

同被引文献118

引证文献10

二级引证文献27

中国临床药理学杂志
2005年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部